查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553487

多发性硬化症药物市场占有率及趋势分析报告：2024-2030 年按药物类别、给药途径、分销管道、地区和细分市场预测

Multiple Sclerosis Therapeutic Market Share & Trends Analysis Report By Drug Class, By Route of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

多发性硬化症药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球多发性硬化症药物市场规模将达到386.2亿美元，2024年至2030年复合年增长率为5.9%。

新兴市场存在大量未满足的临床需求是多发性硬化症药物市场最有影响力的驱动因素之一。世界各地的许多组织都积极参与提高人们对进行性多发性硬化症及其相关症状的认识。着名的例子包括美国国家多发性硬化症协会 (NMSS)、加拿大多发性硬化症国际联合会、欧洲多发性硬化症平台 (EMSP) 和多发性硬化症协会 (MSC)。

报销计画也有望提高多发性硬化症药物的渗透率。例如，2014 年 6 月，Biogen Idec Canada 宣布其多发性硬化症治疗药物 TECFIDERA 现在可透过 BC PharmaCare 在英国哥伦比亚省进行报销。

引入具有成本效益且所需剂量最低的新型疗法预计将进一步促进市场成长。例如，赛诺菲的 Lemtrada 需要每年给药三到五次，而 Copaxone 则需要每天给药。

多发性硬化症药物市场报告亮点

  • 考虑到 FDA核准的强效口服药物 Orvidio 和 Tecfidera 的推出导致这些药物的使用有限等因素，预计 Copaxone、 Gilenya、 Avonex和Tysabri的收益将下降。
  • 另一方面，免疫抑制剂预计将大幅增加18.0%以上。强大的药物管道的存在和未来六年内的预期商业化是预计推动市场成长的一些因素。
  • 2023年，注射剂药品市场因处方率高、价格高而占最大份额。
  • 2023年，北美主导全球多发性硬化症药物市场，份额为38.3%。促成其主导地位的因素包括多发性硬化症盛行率的增加、新药的推出以及美国Tysabri和 Overgeo 等药物的高成本。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章多发性硬化症药物市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多发性硬化症药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章多发性硬化症治疗药物市场：依药物类别估计与趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：2023 年和 2030 年按药物类别分類的波动分析
  • 免疫抑制剂
  • 免疫刺激剂

第五章多发性硬化症治疗药物市场：依途径估计与趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：2023 年和 2030 年按给药途径进行的变异分析
  • 口服
  • 注射
  • 其他的

第六章 多发性硬化症治疗药物市场：按分销管道估计和趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：2023 年和 2030 年按分销管道分類的波动分析
  • 医院药房
  • 零售药房
  • 电子商务

第七章多发性硬化症治疗药物市场：区域估计与趋势分析

  • 2023 年及 2030 年多发性硬化症药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Biogen
    • Bayer AG
    • Sanofi
    • F. Hoffman-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Takeda Pharmaceuticals Company Limited.
    • Horizon Therapeutics plc
简介目录
Product Code: 978-1-68038-833-6

Multiple Sclerosis Therapeutic Market Growth & Trends:

The global multiple sclerosis therapeutic market size is expected to reach USD 38.62 billion by 2030, registering a CAGR of 5.9% from 2024 to 2030, according to a new report by Grand View Research, Inc.

The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Multiple Sclerosis Therapeutic Market Report Highlights:

  • The declining revenue of Copaxone, Gilenya, Avonex, and Tysabri is forecasted by considering the factors such as limited usage rates of these drugs owing to the availability of highly potent FDA-approved oral drugs, Aubigio and Tecfidera
  • Immunosuppressant,on the other hand, is expected to witness significant growth of over 18.0%. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth
  • In 2023, the injectable drugs market held the largest share owing to high prescription rates & price
  • North America dominated the global multiple sclerosis therapeutic market with a share of 38.3% in 2023. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Multiple Sclerosis Therapeutic Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Multiple Sclerosis Therapeutic Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Immunosuppressants
    • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunostimulants
    • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Sclerosis Therapeutic Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Oral
    • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Sclerosis Therapeutic Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. E-Commerce
    • 6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Teva Pharmaceutical Industries Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Biogen
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bayer AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. F. Hoffman-La Roche Ltd
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Johnson & Johnson Services, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Merck & Co., Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Takeda Pharmaceuticals Company Limited.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Horizon Therapeutics plc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives